Digoxin In Treatment of Alcohol Associated Hepatitis
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Prospective, single center, open label, randomized controlled trial to determine the
feasibility of conducting a future study with respect to patient recruitment, digoxin
administration and dose adjustment. The study intervention will be intravenous digoxin
(renal-based dosing for maximum of 28 days) versus no digoxin in an open-label 1:1 randomized
allocation of patients with severe acute alcohol associated hepatitis.